These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36356965)

  • 21. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
    Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
    PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
    Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Kumar P; Ramesh K; Anitha S; Narendran G; Menon P; Gomathi C; Swaminathan S
    Antimicrob Agents Chemother; 2009 Mar; 53(3):863-8. PubMed ID: 19124658
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
    Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
    Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz.
    Mahungu TW; Nair D; Smith CJ; Egan D; Youle M; Johnson MA; Khoo SH; Back DJ; Owen A
    Clin Pharmacol Ther; 2009 Aug; 86(2):204-11. PubMed ID: 19474786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults.
    Cheng L; Wang Y; Li X; Feng W; Weng B; Yuan Q; Xia P; Sun F
    Pharmacogenomics J; 2020 Apr; 20(2):246-259. PubMed ID: 31636355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya.
    Ngayo MO; Oluka M; Kwena ZA; Bulimo WD; Okalebo FA
    PLoS One; 2022; 17(3):e0260872. PubMed ID: 35235559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
    Chen J; Sun J; Ma Q; Yao Y; Wang Z; Zhang L; Li L; Sun F; Lu H
    Ther Drug Monit; 2010 Oct; 32(5):573-8. PubMed ID: 20625352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
    Reay R; Dandara C; Viljoen M; Rheeders M
    OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections.
    Sukasem C; Chamnanphon M; Koomdee N; Puangpetch A; Santon S; Jantararoungtong T; Prommas S; Chantratita W; Manosuthi W
    Drug Metab Pharmacokinet; 2013; 28(5):391-7. PubMed ID: 23399569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
    McIlleron HM; Schomaker M; Ren Y; Sinxadi P; Nuttall JJ; Gous H; Moultrie H; Eley B; Merry C; Smith P; Haas DW; Maartens G
    AIDS; 2013 Jul; 27(12):1933-40. PubMed ID: 24180002
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
    Swart M; Skelton M; Ren Y; Smith P; Takuva S; Dandara C
    Pharmacogenet Genomics; 2013 Aug; 23(8):415-27. PubMed ID: 23778320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.
    Haas DW; Severe P; Jean Juste MA; Pape JW; Fitzgerald DW
    J Antimicrob Chemother; 2014 Aug; 69(8):2187-90. PubMed ID: 24695352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients.
    Yimer G; Ueda N; Habtewold A; Amogne W; Suda A; Riedel KD; Burhenne J; Aderaye G; Lindquist L; Makonnen E; Aklillu E
    PLoS One; 2011; 6(12):e27810. PubMed ID: 22162992
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
    Bertrand J; Verstuyft C; Chou M; Borand L; Chea P; Nay KH; Blanc FX; Mentré F; Taburet AM;
    J Infect Dis; 2014 Feb; 209(3):399-408. PubMed ID: 23990572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efavirenz dosing: influence of drug metabolizing enzyme polymorphisms and concurrent tuberculosis treatment.
    Gengiah TN; Botha JH; Yende-Zuma N; Naidoo K; Abdool Karim SS
    Antivir Ther; 2015; 20(3):297-306. PubMed ID: 25318122
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.
    Habtewold A; Aklillu E; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Owen JS
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
    Haas DW; Kwara A; Richardson DM; Baker P; Papageorgiou I; Acosta EP; Morse GD; Court MH
    J Antimicrob Chemother; 2014 Aug; 69(8):2175-82. PubMed ID: 24729586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.
    Mahungu T; Smith C; Turner F; Egan D; Youle M; Johnson M; Khoo S; Back Dj; Owen A
    HIV Med; 2009 May; 10(5):310-7. PubMed ID: 19228205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
    Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1405-1415. PubMed ID: 30003275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms.
    Lindfelt T; O'Brien J; Song JC; Patel R; Winslow DL
    Ann Pharmacother; 2010 Oct; 44(10):1572-8. PubMed ID: 20841522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.